Notably, Ballinger et al. identified pathogenic germline mutations in 638 (55%) samples among 1162 sarcoma patients, using a targeted exon sequencing panel comprising 72 genes (based on associations with increased cancer risk), including TP53 and RB [42]. This evidence concerns the gene TP53 and cancer.